BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24463217)

  • 1. Specific targeting of tumor cells by lyophilisomes functionalized with antibodies.
    van Bracht E; Stolle S; Hafmans TG; Boerman OC; Oosterwijk E; van Kuppevelt TH; Daamen WF
    Eur J Pharm Biopharm; 2014 May; 87(1):80-9. PubMed ID: 24463217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cellular uptake of albumin-based lyophilisomes when functionalized with cell-penetrating peptide TAT in HeLa cells.
    van Bracht E; Versteegden LR; Stolle S; Verdurmen WP; Woestenenk R; Raavé R; Hafmans T; Oosterwijk E; Brock R; van Kuppevelt TH; Daamen WF
    PLoS One; 2014; 9(11):e110813. PubMed ID: 25369131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lyophilisomes as a new generation of drug delivery capsules.
    van Bracht E; Raavé R; Verdurmen WP; Wismans RG; Geutjes PJ; Brock RE; Oosterwijk E; van Kuppevelt TH; Daamen WF
    Int J Pharm; 2012 Dec; 439(1-2):127-35. PubMed ID: 23069914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cells.
    Kouchakzadeh H; Shojaosadati SA; Mohammadnejad J; Paknejad M; Rasaee MJ
    Hum Antibodies; 2012; 21(3-4):49-56. PubMed ID: 23549021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer.
    Esfandyari-Manesh M; Mohammadi A; Atyabi F; Nabavi SM; Ebrahimi SM; Shahmoradi E; Varnamkhasti BS; Ghahremani MH; Dinarvand R
    Int J Pharm; 2016 Dec; 515(1-2):607-615. PubMed ID: 27989825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution of size-selected lyophilisomes in mice.
    van Bracht E; Raavé R; Perevyazko IY; Versteeg EM; Hafmans TG; Schubert US; Oosterwijk E; van Kuppevelt TH; Daamen WF
    Eur J Pharm Biopharm; 2015 Aug; 94():141-51. PubMed ID: 25953331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells.
    Cai L; Qiu N; Li X; Luo K; Chen X; Yang L; He G; Wei Y; Chen L
    Int J Pharm; 2011 Apr; 408(1-2):173-82. PubMed ID: 21277964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core-shell nanoparticles.
    Varnamkhasti BS; Hosseinzadeh H; Azhdarzadeh M; Vafaei SY; Esfandyari-Manesh M; Mirzaie ZH; Amini M; Ostad SN; Atyabi F; Dinarvand R
    Int J Pharm; 2015 Oct; 494(1):430-44. PubMed ID: 26315125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
    Yu C; Hu Y; Duan J; Yuan W; Wang C; Xu H; Yang XD
    PLoS One; 2011; 6(9):e24077. PubMed ID: 21912664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and characterization of lipid immuno-nanocapsules for directed drug delivery: selective antitumor activity against HER2 positive breast-cancer cells.
    Sánchez-Moreno P; Ortega-Vinuesa JL; Boulaiz H; Marchal JA; Peula-García JM
    Biomacromolecules; 2013 Dec; 14(12):4248-59. PubMed ID: 24134122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the extracellular matrix of ovarian cancer using functionalized, drug loaded lyophilisomes.
    van der Steen SC; Raavé R; Langerak S; van Houdt L; van Duijnhoven SM; van Lith SA; Massuger LF; Daamen WF; Leenders WP; van Kuppevelt TH
    Eur J Pharm Biopharm; 2017 Apr; 113():229-239. PubMed ID: 28034806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.
    Wagner S; Rothweiler F; Anhorn MG; Sauer D; Riemann I; Weiss EC; Katsen-Globa A; Michaelis M; Cinatl J; Schwartz D; Kreuter J; von Briesen H; Langer K
    Biomaterials; 2010 Mar; 31(8):2388-98. PubMed ID: 20031203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.
    Taheri A; Dinarvand R; Atyabi F; Ghahremani MH; Ostad SN
    Eur J Pharm Sci; 2012 Sep; 47(2):331-40. PubMed ID: 22771547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies.
    Zheng Y; Cai Z; Song X; Chen Q; Bi Y; Li Y; Hou S
    J Drug Target; 2009 May; 17(4):294-303. PubMed ID: 19255895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.
    Hasegawa M; Sinha RK; Kumar M; Alam M; Yin L; Raina D; Kharbanda A; Panchamoorthy G; Gupta D; Singh H; Kharbanda S; Kufe D
    Clin Cancer Res; 2015 May; 21(10):2338-47. PubMed ID: 25712682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
    Steinhauser I; Spänkuch B; Strebhardt K; Langer K
    Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clickable protein nanocapsules for targeted delivery of recombinant p53 protein.
    Zhao M; Liu Y; Hsieh RS; Wang N; Tai W; Joo KI; Wang P; Gu Z; Tang Y
    J Am Chem Soc; 2014 Oct; 136(43):15319-25. PubMed ID: 25289975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells.
    Sadeqzadeh E; Rahbarizadeh F; Ahmadvand D; Rasaee MJ; Parhamifar L; Moghimi SM
    J Control Release; 2011 Nov; 156(1):85-91. PubMed ID: 21704663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells.
    Maya S; Kumar LG; Sarmento B; Sanoj Rejinold N; Menon D; Nair SV; Jayakumar R
    Carbohydr Polym; 2013 Apr; 93(2):661-9. PubMed ID: 23499109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.